nach oben

Erschienen in:

11.12.2015 | Original Article—Alimentary Tract

Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes

verfasst von: Christoffer Soendergaard, Peter Helding Kvist, Jakob Benedict Seidelin, Hermann Pelzer, Ole Haagen Nielsen

Erschienen in: Journal of Gastroenterology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Subunit A of coagulation factor XIII (FXIII-A) is important for clot stability and acts in the subsequent wound healing process. Loss of plasma FXIII-A has been reported after surgery, sepsis, and inflammatory conditions. In the intestinal mucosa, FXIII-A is expressed by macrophages and cellular FXIII-A has been associated with phagocytosis and migration of macrophages. The objective was to evaluate the consequences of intestinal inflammation on resident mucosal macrophages, focusing on the level and distribution of FXIII-A.

Methods

Plasma and colonic biopsies were collected from 67 patients with ulcerative colitis and controls. Intestinal samples were stained using immunohistochemistry for FXIII-A and macrophages (CD68, CD163 and iNOS). In situ hybridization were used to assess the intestinal expression of FXIII-A. FXIII-A antigen and activity levels were measured in plasma.

Results

Increased infiltration of CD68 positive macrophages in the inflamed mucosa coincided with increased extracellular deposited FXIII-A and decreased expression and intracellular protein levels of FXIII-A. A decreased proportion of FXIII-A/CD68/CD163 triple-positive macrophages was observed in inflamed mucosa, indicating a reduction of the M2 phenotype with consequent loss of FXIII-A. No induction of iNOS positive macrophages was observed. Stimulation of naïve monocytes with physiological concentrations of pro-inflammatory mediators negatively affected the expression of FXIII-A. Measurements in plasma confirmed the loss of both FXIII antigen and activity during active disease.

Conclusions

Intestinal inflammation in UC induces loss of M2 macrophages with subsequent loss of FXIII-A synthesis. The loss of cellular FXIII-A may impact migration and phagocytosis, and hence limit pathogen eradication in UC.

Nur mit Berechtigung zugänglich

Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost. 2013;11:234–44.CrossRefPubMed

Muszbek L, Bereczky Z, Bagoly Z, et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931–72.CrossRefPubMed

Dickneite G, Herwald H, Korte W, et al. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost. 2015;113:686–97.CrossRefPubMed

Soendergaard C, Kvist PH, Seidelin JB, et al. Tissue-regenerating functions of coagulation factor XIII. J Thromb Haemost. 2013;11:806–16.CrossRefPubMed

Dardik R, Loscalzo J, Eskaraev R, et al. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol. 2005;25:526–32.CrossRefPubMed

Zaets SB, Xu DZ, Lu Q, et al. Recombinant factor XIII diminishes multiple organ dysfunction in rats caused by gut ischemia-reperfusion injury. Shock. 2009;31:621–6.CrossRefPubMedPubMedCentral

Zaets SB, Xu DZ, Lu Q, et al. Recombinant factor XIII mitigates hemorrhagic shock-induced organ dysfunction. J Surg Res. 2011;166:e135–42.CrossRefPubMed

Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood. 2011;118:2589–98.CrossRefPubMed

Bagoly Z, Katona E, Muszbek L. Factor XIII and inflammatory cells. Thromb Res. 2012;129(Suppl 2):S77–81.CrossRefPubMed

10.

Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–19.CrossRefPubMed

11.

Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.CrossRefPubMed

12.

Kamitsuji H, Tani K, Yasui M, et al. Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schonlein purpura. Efficacy of factor XIII substitution. Eur J Pediatr. 1987;146:519–23.CrossRefPubMed

13.

Song JW, Choi JR, Song KS, et al. Plasma factor XIII activity in patients with disseminated intravascular coagulation. Yonsei Med J. 2006;47:196–200.CrossRefPubMedPubMedCentral

14.

Ogawa T, Morioka Y, Inoue T, et al. Involvement of blood coagulation factor XIII in burn healing in the carbon tetrachloride-induced hepatic injury model in rats. Inflamm Res. 1995;44:264–8.CrossRefPubMed

15.

D’Argenio G, Cosenza V, Riegler G, et al. Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis. Dig Dis Sci. 2001;46:649–57.CrossRefPubMed

16.

Burkhardt H, Zellner PR. Moller I [Factor XIII deficiency in burns]. Chirurg. 1977;48:520–3.PubMed

17.

Zeerleder S, Schroeder V, Lammle B, et al. Factor XIII in severe sepsis and septic shock. Thromb Res. 2007;119:311–8.CrossRefPubMed

18.

Higaki S, Nakano K, Onaka S, et al. Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn’s disease. J Gastroenterol Hepatol. 2006;21:1407–11.PubMed

19.

Wolpl A, Lattke H, Board PG, et al. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation. 1987;43:151–3.CrossRefPubMed

20.

Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94:271–305.CrossRefPubMed

21.

Adany R, Bardos H. Factor XIII subunit A as an intracellular transglutaminase. Cell Mol Life Sci. 2003;60:1049–60.PubMed

22.

Myneni VD, Hitomi K, Kaartinen MT. Factor XIII-A transglutaminase acts as a switch between preadipocyte proliferation and differentiation. Blood. 2014;124:1344–53.CrossRefPubMed

23.

Nurminskaya M, Kaartinen MT. Transglutaminases in mineralized tissues. Front Biosci. 2006;11:1591–606.CrossRefPubMed

24.

Kaetsu H, Hashiguchi T, Foster D, et al. Expression and release of the a and b subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells. J Biochem. 1996;119:961–9.CrossRefPubMed

25.

Cordell PA, Kile BT, Standeven KF, et al. Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion. Blood. 2010;115:2674–81.CrossRefPubMed

26.

Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.CrossRefPubMed

27.

Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.CrossRefPubMedPubMedCentral

28.

Torocsik D, Bardos H, Nagy L, et al. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell Mol Life Sci. 2005;62:2132–9.CrossRefPubMed

29.

Spiller R. Clinical update: irritable bowel syndrome. Lancet. 2007;369:1586–8.CrossRefPubMed

30.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.CrossRefPubMed

31.

Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–9.CrossRefPubMedPubMedCentral

32.

Soendergaard C, Nielsen OH, Skak K, et al. Objective quantification of immune cell infiltrates and epidermal proliferation in psoriatic skin—a comparison of digital image analysis and manual counting. Appl Immunohistochem Mol Morphol. 2015;[Epub ahead of print].

33.

Linskens RK, van Bodegraven AA, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001;46:644–8.CrossRefPubMed

34.

Chiarantini E, Valanzano R, Liotta AA, et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 1996;82:137–46.CrossRefPubMed

35.

Hayat M, Ariens RA, Moayyedi P, et al. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:249–56.CrossRefPubMed

36.

Seitz R, Leugner F, Katschinski M, et al. Ulcerative colitis and Crohn’s disease: factor XIII, inflammation and haemostasis. Digestion. 1994;55:361–7.CrossRefPubMed

37.

Vrij AA, Rijken J, van Wersch JW, et al. Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis. Haemostasis. 1999;29:326–35.PubMed

38.

Stadnicki A, Kloczko J, Nowak A, et al. Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis. Am J Gastroenterol. 1991;86:690–3.PubMed

39.

Wang Z, Wilhelmsson C, Hyrsl P, et al. Pathogen entrapment by transglutaminase—a conserved early innate immune mechanism. PLoS Pathog. 2010;6:e1000763.CrossRefPubMedPubMedCentral

40.

D’Argenio G, Calvani M, Della VN, et al. Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis. Gut. 2005;54:496–502.CrossRefPubMedPubMedCentral

41.

Takabayashi T, Kato A, Peters AT, et al. Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2013;132:584–92.CrossRefPubMedPubMedCentral

42.

Plenz A, Fritz P, Konig G, et al. Immunohistochemical detection of factor XIIIa and factor XIIIs in synovial membranes of patients with rheumatoid arthritis or osteoarthritis. Rheumatol Int. 1996;16:29–36.CrossRefPubMed

43.

Bain CC, Scott CL, Uronen-Hansson H, et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013;6:498–510.CrossRefPubMed

44.

Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4⁺ Th1 cells. J Immunol. 2011;187:1157–65.CrossRefPubMed

45.

Lissner D, Schumann M, Batra A, et al. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm Bowel Dis. 2015;21:1297–305.PubMedPubMedCentral

46.

Torocsik D, Bardos H, Hatalyak Z, et al. Detection of factor XIII-A is a valuable tool for distinguishing dendritic cells and tissue macrophages in granuloma annulare and necrobiosis lipoidica. J Eur Acad Dermatol Venereol. 2014;28:1087–96.CrossRefPubMed

47.

Zaba LC, Fuentes-Duculan J, Steinman RM, et al. Normal human dermis contains distinct populations of CD11c⁺BDCA-1⁺ dendritic cells and CD163⁺FXIIIA⁺ macrophages. J Clin Invest. 2007;117:2517–25.CrossRefPubMedPubMedCentral

48.

Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol. 2009;182:4415–22.CrossRefPubMed

49.

Sarvary A, Szucs S, Balogh I, et al. Possible role of factor XIII subunit A in Fcgamma and complement receptor-mediated phagocytosis. Cell Immunol. 2004;228:81–90.CrossRefPubMed

50.

Torocsik D, Szeles L, Paragh G Jr, et al. Factor XIII-A is involved in the regulation of gene expression in alternatively activated human macrophages. Thromb Haemost. 2010;104:709–17.CrossRefPubMed

51.

Jayo A, Conde I, Lastres P, et al. Possible role for cellular FXIII in monocyte-derived dendritic cell motility. Eur J Cell Biol. 2009;88:423–31.CrossRefPubMed

Titel: Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes
verfasst von: Christoffer Soendergaard
Peter Helding Kvist
Jakob Benedict Seidelin
Hermann Pelzer
Ole Haagen Nielsen
Publikationsdatum: 11.12.2015
Verlag: Springer Japan
Erschienen in: Journal of Gastroenterology / Ausgabe 8/2016
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-015-1152-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes

Abstract

Background

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice

Gastrointestinal mucosal barrier function and diseases

The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease

Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015

Lower body mass index predicts worse cancer-specific prognosis in octogenarians with colorectal cancer

Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin